[1] Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J,2019,53:1801913.
[2] Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol,1987,10: 1233-1238.
[3] Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol,2011,179: 167-179.
[4] Mantz FA Jr, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol,1951,52: 91-97.
[5] Ba Desch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. CHEST, 2010,137:376-387.
[6] Thomas C, Glinskii V, de Jesus Perez V, et al. Portopulmonary Hypertension: From Bench to Bedside. Front Med (Lausanne),2020,7: 569413.
[7] Segraves JM, Cartin-Ceba R, Leise MD, et al. Relationship between portopulmonary hypertension and splenectomy: Mayo Clinic experience and literature review. Hepatol Res,2017. 48:E340-E346.
[8] Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med,1996,17: 151-169.
[9] Lv Y, Han G, Fan D. Portopulmonary hypertension. Scand J Gastroenterol,2016,51: 795-806.
[10] Raevens S, Geerts A, Van Steenkiste C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int,2015,35: 1646-1660.
[11] Savale L, Watherald J, Sitbon O. Portopulmonary Hypertension. Semin Respir Crit Care Med,2017,38: 651-661.
[12] DuBrock HM, Channick RN, Krowka MJ. What's new in the treatment of portopulmonary hypertension. Expert Rev Gastroenterol Hepatol,2015,9: 983-992.
[13] Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest,2003,123: 562-576.
[14] Wong F. Portopulmonary hypertension in cirrhosis: the pathogenetic challenge. Gut,2005,54: 309.
[15] Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res,2011,63: 504-511.
[16] Cartin-Ceba R, Krowka MJ. Pulmonary Complications of Portal Hypertension. Clin Liver Dis,2019,23: 683-711.
[17] Fussner LA, Krowka MJ. Current Approach to the Diagnosis and Management of Portopulmonary Hypertension. Curr Gastroenterol Rep,2016,18: 29.
[18] Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J,2019,53:1801887.
[19] Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation,2016,100: 1440-1452.
[20] de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepato,2015,63: 743-752.
[21] Baeyens N, Bandyopadhyay C, Coon BG, et al. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest,2016,126: 821-828.
[22] Cartin-Ceba R, Krowka MJ. Portopulmonary hypertension. Clin Liver Dis,2014,18: 421-438.
[23] Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology,2008,48: 2064-2077.
[24] Park SC, Beerman LB, Gartner JC, et al. Echocardiographic findings before and after liver transplantation. Am J Cardiol,1985,55: 1373-1378.
[25] Elisabeth Miot-Noirault LF, Yves Guichard JM, Pape AL. Scintigraphic in vivo assessment of the development of pulmonary intravascular macrophages in liver disease: experimental study in rats with biliary cirrhosis. CHEST,2001,120: 941-947.
[26] Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med,2001,164:879-885.
[27] Pellicelli AM, Barbaro G, Puoti C,?et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. ANGIOLOGY,2010,61:802-806.
[28] Turco L, Garcia-Tsao G, Magnani I, et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol,?2018, 68:949-958.
[29] 殷鑫. 肝硬化并发门脉性肺动脉高压患者的临床特征分析. 吉林大学,2020.
[30] Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet,2000,26: 81-84.
[31] Desroches-Castan A, Tillet E, Ricard N, et al. Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting Against Hepatic Fibrosis. Hepatology,2019,70: 1392-1408.
[32] Rochon ER, Krowka MJ, Bartolome S, et al. BMP 9/10 in Pulmonary Vascular Complications of Liver Disease. Am J Resp Crit Care, 2020,201.
[33] Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med,2015,21:777-785..
[34] Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology,2008,48: 196-203.
[35] Chen H, Wang F, Xiao J, et al. Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension. Arch Med Sci,2014,10: 1055-1056.
[36] Koksal D, Koksal AS, Gurakar A. Pulmonary Manifestations among Patients with Primary Biliary Cirrhosis. J Clin Transl Hepatol.2016,4:258-262.
[37] Terao M, Takaki A, Maruyama T, et al. Serum Oxidative/anti-oxidative Stress Balance Is Dysregulated in Potentially Pulmonary Hypertensive Patients with Liver Cirrhosis: A Case Control Study. Intern Med,2015,54:2815-2826.
[38] 刘以俊, 李涛. 《2016年国际肝移植学会实践指南:肝肺综合征与门脉性肺动脉高压的诊断与管理》摘译. 临床肝胆病杂志,2016,32: 1838-1842.
[39] Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J,2019,53:1801913.
[40] Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology,2003, 37: 401-409.
[41] Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed),2016,69:177.
[42] Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med,2013,369: 809-818.
[43] Sidharta PN, Lindegger N, Ul I, et al. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.J Clin Pharmacol,2014,54:291-300.
[44] Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial - ScienceDirect. J Heart Lung Transplant,2020,39:464-472.
[45] 徐杰, 史阳阳, 孙凯. 门脉性肺动脉高压发病机制及治疗的最新研究进展. 医学综述,2021,27: 2503-2508.
[46] Cartin-Ceba R, Halank M, Ghofrani HA, et al. Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. Pulm Circ, 2018, 8:2045894018769305.
[47] Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl,2000,6:443-450.
[48] Savale L, Sattler C, Coilly A, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology (Baltimore, Md.). 2017.
[49] Bandara M, Gordon FD, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Hepatology,2017,65:1683-1692.
[50] Grannas G, Neipp M, Hoeper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation, 2008, 85: 524-531. |
